GrifolsMEX:GRFP N 83 Interest Coverage is 1.79 as of Mar. 2026, which is 39% below its 10-year median of 2.94. GuruFocus rates MEX:GRFP N with a GF Score™ of 83/100 and a GF Value™ of MXN154.24. The stock has 6 warning signs investors should review. Among 685 Drug Manufacturers companies, Grifols ranks worse than 83.8% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Grifols's
Operating Income
for the
three
months ended in Mar. 2026 was MXN5,191 Mil. Grifols's Interest Expense for the
three
months ended in Mar. 2026 was MXN-2,898 Mil.
Grifols's interest coverage for the quarter that ended in Mar. 2026 was 1.79.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Grifols SA interest coverage is 2.25, which is low.
The historical rank and industry rank for Grifols's Interest Coverage or its related term are showing as below:
MEX:GRFP N'
s Interest Coverage Range Over the Past 10 Years
Min: 1.39 Med: 2.94 Max: 4.38
Current: 2.25
MEX:GRFP N's Interest Coverage is ranked worse than 83.8% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs MEX:GRFP N: 2.25
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Grifols Interest Coverage Related Terms
Grifols Interest Coverage Historical Data
* Premium members only.
The historical data trend for Grifols's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:GRFP N vs LLY, JNJ, ABBV: Interest Coverage Comparison
For the Drug Manufacturers - General subindustry, Grifols's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Grifols's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (MEX:GRFP N) has a Interest Coverage of 1.79 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Grifols and its competitors. This is 39% below median its historical median of 2.94. Over the past decade, Grifols' Interest Coverage has ranged from 1.39 to 4.38. According to the industry distribution chart, Grifols ranks #574 out of 685 companies in the Drug Manufacturers industry, placing it in the top 83.8%.
Is Grifols' Interest Coverage too high?
Grifols' current Interest Coverage of 1.79 is 39% below median its 10-year median of 2.94. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 4.38. The Drug Manufacturers industry median Interest Coverage is 12.78. Grifols' value of 1.79 is 86% below this industry median. Based on the distribution chart, Grifols ranks #574 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grifols has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' Interest Coverage compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #574 out of 685 companies for Interest Coverage. This places Grifols in the lower half of its industry. The industry median Interest Coverage is 12.78. Grifols' value of 1.79 is 86% below this benchmark. Historically, Grifols' own Interest Coverage has ranged from 1.39 to 4.38 over the past decade. While the company's 10-year median is 2.94 vs. the industry median of 12.78, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Interest Coverage of 1.79 is 86% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Interest Coverage is 1.79, which is 39% below median its own 10-year median of 2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (MEX:GRFP N) has a current Interest Coverage of 1.79. The stock's GF Value™ is MXN154.24, compared to a current price of MXN126.63 — trading 17.9% below its estimated fair value. The current Interest Coverage is 1.79, which is 39% below median its 10-year median of 2.94 and 86% below the Drug Manufacturers industry median of 12.78. Grifols' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Grifols (MEX:GRFP N), the current Interest Coverage is 1.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (MEX:GRFP N) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of MXN126.63 is trading 17.9% below its estimated GF Value™ of MXN154.24.
Key valuation signals for MEX:GRFP N:
Interest Coverage: 1.79 (39% below median its 10-year median of 2.94)
GF Value™: MXN154.24 vs. price of MXN126.63 (17.9% below fair value)
Industry Position: 86% below the Drug Manufacturers median (#574 of 685)
No single metric tells the full story. See the MEX:GRFP N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score
Get the complete analysis for MEX:GRFP N
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GRFP N has been successfully added to your 
